We are pleased to announce that an article featuring Gel Coat Biomaterials' biologics stabilization platform technology, Gel Coat™, was published in Nikkei Biotechnology Online on June 30, 2026.
The article highlights Gel Coat™, our biologics stabilization platform based on our proprietary nanoparticle hydrogel technology, and introduces both the technological advances and business development activities of Gel Coat Biomaterials.
Biomolecules such as enzymes and proteins, which are widely used in biopharmaceuticals, vaccines, regenerative medicine products, and diagnostic reagents, are highly sensitive to temperature and storage conditions. As a result, strict temperature control throughout manufacturing, storage, and transportation is often required. Dependence on cold-chain logistics presents significant challenges, including increased distribution costs, limited accessibility in certain regions, and difficulties in maintaining stable supply during natural disasters or in areas where cold-chain infrastructure is insufficient.
Gel Coat™ is a platform technology developed by Gel Coat Biomaterials to improve the storage stability of biomolecules through a simple formulation-based approach, without chemically modifying the active ingredients themselves. Because it can be readily incorporated into existing manufacturing processes, the technology has the potential to suppress degradation during storage while preserving the native functionality of biomolecules.
In validation studies using enzymes that conventionally require ultra-low-temperature storage at −30°C, Gel Coat™ maintained more than 80% of enzymatic activity after 28 days of storage at 4°C. Ongoing studies are also evaluating its ability to improve storage stability under room-temperature and elevated-temperature conditions.
Figure 1. Comparison of Enzyme Activity Retention Between Conventional Storage and Gel Coat™ Formulation
The Gel Coat™ formulation maintained more than 80% enzyme activity after 28 days of storage at 4°C, demonstrating a significant improvement in storage stability.
Left: Conventional storage without Gel Coat™.Right: Storage with Gel Coat™ formulation.
The article also introduces our ongoing research into safety evaluations and pharmacokinetic design for future human applications. Looking ahead, Gel Coat Biomaterials plans to expand the application of Gel Coat™ beyond in vitro diagnostics to regenerative medicine and biopharmaceutical products, while accelerating joint research and licensing activities with pharmaceutical companies and regenerative medicine partners.
In addition, the article highlights the strong international interest in our technology demonstrated during BIO International Convention 2026, where meetings with several global pharmaceutical companies provided new opportunities for future collaboration. Building on these achievements, Gel Coat Biomaterials is further strengthening its partnering activities through joint research, technology evaluation, and strategic business collaborations.
Gel Coat Biomaterials will continue advancing innovative biomaterials based on its proprietary nanoparticle hydrogel technology while promoting collaborative research and product development with partners worldwide. Through these efforts, we remain committed to addressing key challenges in the life sciences and accelerating the practical implementation of our technologies.
Media Coverage
Nikkei Biotechnology Online
Featured Article
Please note that access to the article may require a subscription to Nikkei Biotechnology Online.
